Beyond glycaemic control: A cross-over, double-blinded, 24-week intervention with liraglutide in type 1 diabetes.
Dubé, Marie-Christine; D'Amours, Martin; Weisnagel, S John.
Diabetes Obes Metab
; 20(1): 178-184, 2018 01.
Artigo em Inglês | MEDLINE | ID: mdl-28722271
Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
GLP-1 Agonists in Type 1 Diabetes Mellitus.
Exposure-response analyses of liraglutide 3.0 mg for weight management.
Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Chronic liraglutide therapy induces an enhanced endogenous glucagon-like peptide-1 secretory response in early type 2 diabetes.
Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences.
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
Effect of liraglutide on dietary lipid-induced insulin resistance in humans.